Skip to content
value.today

Compass Therapeutics, Inc.

CMPX
$137 Mmarket cap on Oct 29, 2026-30.9% since Jan 2024
Compare
World rank
#17,617
Revenue
$0 M
For year ending December-2025
value.today research
Net income
$-66 M
value.today research
Employees
39
As of December 31, 2025
SEC filing

Compass Therapeutics, Inc. in brief

Compass Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. Its market value was $137 M on 29 October 2026, which makes it the 17,617th largest listed company in the world and the 3,354th largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $66 M. It employs about 39 people and Thomas J. Schuetz is its chief executive. Its shares trade under the symbol CMPX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Compass Therapeutics, Inc.

We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development and commercialization as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.

From the company's annual report filed with the US SEC: read the report

Compass Therapeutics, Inc. timeline

2 events, 2018–2020
  1. 2018
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2020
  4. ✎
    Renamed Compass Therapeutics, Inc.
    Formerly Olivia Ventures, Inc..

Events of Compass Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$265 M$529 M$794 M$1.1 B2023202420252026

World rank over time

▼ down 1,279 places since 2022
2022-01-07: #16369#16,36920222022-12-25: #10485#10,48520222023-07-30: #15164#15,16420232024-01-05: #17956#17,95620242026-03-08: #4778#4,77820262026-08-01: #13088#13,08820262026-10-14: #17254#17,25420262026-10-29: #17648#17,6482026

Rank in USA: #3,393 (Jan 2022) · #2,322 (Dec 2022) · #3,077 (Jul 2023) · #3,255 (Jan 2024) · #874 (Mar 2026) · #2,661 (Aug 2026) · #3,268 (Oct 2026) · #3,358 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.7×
Free cash flow yield
-35.9%
Net margin
—
Operating margin
—
Return on equity
-33.8%
Liabilities / assets
10.4%
Net debt
$-145M
R&D / revenue
4981.2%
Revenue per employee
$0 K
Profit per employee
$-1.7 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue —, net income $-35M—FY19Fiscal year ending Dec 2020: revenue —, net income $-30M—FY20Fiscal year ending Dec 2021: revenue —, net income $-82M—FY21Fiscal year ending Dec 2022: revenue —, net income $-39M—FY22Fiscal year ending Dec 2023: revenue —, net income $-42M—FY23Fiscal year ending Dec 2024: revenue $1M, net income $-49M$1MFY24Fiscal year ending Dec 2025: revenue —, net income $-66M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-73M$-66M—
Dec 2024$1M—$-57M$-49M-5809.4%
Dec 2023——$-50M$-42M—
Dec 2022——$-42M$-39M—
Dec 2021——$-82M$-82M—
Dec 2020——$-28M$-30M—
Dec 2019——$-34M$-35M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-49M$0M$-49M——
Dec 2024$-45M$0M$-45M——
Dec 2023$-41M$0M$-41M——
Dec 2022$-34M$0M$-34M——
Dec 2021$-20M$2M$-21M$-1.31—
Dec 2020$-27M$0M$-27M$-0.96—
Dec 2019$-32M$0M$-32M$-5.19—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-15M—Dec ’24Three months to Mar 2025: revenue —, net income $-17M—Mar ’25Three months to Jun 2025: revenue —, net income $-20M—Jun ’25Three months to Sep 2025: revenue —, net income $-14M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-16M—Dec ’25Three months to Mar 2026: revenue —, net income $-18M—Mar ’26Three months to Jun 2026: revenue —, net income $-25M—Jun ’26Three months to Sep 2026: revenue —, net income $-27M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-27M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Compass Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-73 M
Net income
$-66 M

For year ending December-2025

Balance sheet

Total assets
$220 M
Total liabilities
$23 M
Total equity
$197 M

As of December-2025

Top 100 institutional investors in Compass Therapeutics, Inc.#

As of Sep 30, 2026
172 institutions held 160.6 M shares (about 89.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 53.6%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Compass Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Tang Capital Management LLC17,990,7820 (0.00%)9.99%$19 MNov 16, 2026
2Orbimed Advisors LLC15,219,9940 (0.00%)8.45%$16 MNov 16, 2026
3Montanova Capital, LLC14,326,988+225,829 (+1.60%)7.96%$15 MNov 16, 2026
4BlackRock, Inc.11,394,556+112,775 (+1.00%)6.33%$12 MNov 13, 2026
5Enavate Sciences GP, LLC7,788,1500 (0.00%)4.32%$8 MNov 16, 2026
6State Street Corp7,737,938-2,215,715 (-22.26%)4.30%$8 MNov 12, 2026
7Palo Alto Investors LP7,148,673+1,316,860 (+22.58%)3.97%$7 MNov 16, 2026
8Vanguard Capital Management LLC5,994,782-124,000 (-2.03%)3.33%$6 MNov 13, 2026
9Millennium Management LLC4,686,422-26,825 (-0.57%)2.60%$5 MNov 16, 2026
10Qube Research & Technologies Ltd4,170,894+483,405 (+13.11%)2.32%$4 MNov 13, 2026
11Geode Capital Management, LLC3,644,115-171,074 (-4.48%)2.02%$4 MNov 6, 2026
12Rock Springs Capital Management LP3,524,9290 (0.00%)1.96%$4 MNov 16, 2026
13Vivo Capital, LLC3,423,547-4,333,513 (-55.87%)1.90%$4 MNov 13, 2026
14Goldman Sachs Group Inc3,394,871-136,129 (-3.86%)1.89%$4 MNov 16, 2026
15Blue Owl Capital Holdings LP3,154,076-470,000 (-12.97%)1.75%$3 MNov 13, 2026
16HRT Financial LP2,662,384+2,492,282 (+1465.17%)1.48%$3 MNov 13, 2026
17Acadian Asset Management LLC2,635,682+1,474,451 (+126.97%)1.46%$3 MNov 9, 2026
18Citadel Advisors LLC2,138,002-1,432,672 (-40.12%)1.19%$2 MNov 16, 2026
19Vanguard Portfolio Management LLC2,077,875-1,693,157 (-44.90%)1.15%$2 MNov 13, 2026
20AQR Capital Management LLC1,975,133-1,534,004 (-43.71%)1.10%$2 MNov 16, 2026
21Fisher Asset Management, LLC1,945,821+553,931 (+39.80%)1.08%$2 MNov 6, 2026
22FMR LLC1,797,306+585,110 (+48.27%)1.00%$2 MNov 10, 2026
23D. E. Shaw & Co., Inc.1,746,286+1,541,799 (+753.98%)0.97%$2 MNov 16, 2026
24Marshall Wace, LLP1,707,238+1,372,369 (+409.82%)0.95%$2 MNov 13, 2026
25Birchview Capital, LP1,575,000-100,000 (-5.97%)0.87%$2 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Compass Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Morgan Stanley1,494,654+759,468 (+103.30%)0.83%$2 MNov 13, 2026
27Algert Global LLC1,458,278+1,150,168 (+373.30%)0.81%$2 MNov 17, 2026
28Squarepoint Ops LLC1,389,796+382,289 (+37.94%)0.77%$1 MNov 9, 2026
29Arrowstreet Capital, Limited Partnership1,208,004New0.67%$1 MNov 13, 2026
30Northern Trust Corp1,089,228-51,686 (-4.53%)0.60%$1 MNov 16, 2026
31Vanguard Fiduciary Trust Co973,188-27,750 (-2.77%)0.54%$1 MNov 13, 2026
32Royce & Associates LP888,393-448,387 (-33.54%)0.49%$1 MNov 9, 2026
33Dimensional Fund Advisors LP855,724+314,546 (+58.12%)0.48%$1 MNov 4, 2026
34Susquehanna International Group, LLP775,923+467,628 (+151.68%)0.43%$1 MNov 16, 2026
35KVP Capital Advisors, LP771,0000 (0.00%)0.43%$1 MNov 16, 2026
36Two Sigma Investments, LP769,443+449,131 (+140.22%)0.43%$1 MNov 16, 2026
37CM Management, LLC750,000+200,000 (+36.36%)0.42%$1 MNov 12, 2026
38Burkehill Global Management, LP700,0000 (0.00%)0.39%$1 MNov 16, 2026
39Connor, Clark & Lunn Investment Management Ltd.677,252+153,475 (+29.30%)0.38%$1 MNov 10, 2026
40Quadrature Capital Ltd638,820+530,570 (+490.13%)0.35%$1 MNov 13, 2026
41Citigroup Inc615,135-98,772 (-13.84%)0.34%$1 MNov 4, 2026
42Exome Asset Management LLC511,084+234,919 (+85.06%)0.28%$1 MNov 16, 2026
43Walleye Capital LLC492,913New0.27%$1 MNov 13, 2026
44Bank Of America Corp /de/464,382-102,537 (-18.09%)0.26%$0 MNov 16, 2026
45Wellington Management Group LLP459,036+80,349 (+21.22%)0.25%$0 MNov 16, 2026
46Jacobs Levy Equity Management, Inc449,301New0.25%$0 MNov 16, 2026
47Charles Schwab Investment Management Inc430,889+127,750 (+42.14%)0.24%$0 MNov 16, 2026
48UBS Group AG423,370-289,393 (-40.60%)0.24%$0 MNov 10, 2026
49Nuveen, LLC387,282-623,280 (-61.68%)0.22%$0 MNov 10, 2026
50Caption Management, LLC385,471+121,894 (+46.25%)0.21%$0 MNov 16, 2026
51Gsa Capital Partners LLP373,703+303,524 (+432.50%)0.21%$0 MNov 16, 2026
52Bank of New York Mellon Corp351,830+798 (+0.23%)0.20%$0 MNov 5, 2026
53Natixis310,800+13,085 (+4.40%)0.17%$0 MNov 6, 2026
54Jpmorgan Chase & Co303,853-485,546 (-61.51%)0.17%$0 MNov 12, 2026
55XTX Topco Ltd290,710+73,225 (+33.67%)0.16%$0 MNov 16, 2026
56Point72 Asset Management, L.P.289,033-397,544 (-57.90%)0.16%$0 MNov 16, 2026
57Voleon Capital Management LP265,130New0.15%$0 MNov 16, 2026
58Acuta Capital Partners, LLC251,001-344,212 (-57.83%)0.14%$0 MNov 16, 2026
59Vestcor Inc239,888New0.13%$0 MNov 12, 2026
60Alps Advisors Inc236,892+54,115 (+29.61%)0.13%$0 MNov 3, 2026
61Rafferty Asset Management, LLC208,702+18,576 (+9.77%)0.12%$0 MNov 13, 2026
62Panagora Asset Management Inc202,635-19,544 (-8.80%)0.11%$0 MNov 12, 2026
63DV Equities, LLC193,034-40,032 (-17.18%)0.11%$0 MNov 16, 2026
64Seven Fleet Capital Management LP193,034-40,032 (-17.18%)0.11%$0 MNov 16, 2026
65Creative Planning161,774-21,067 (-11.52%)0.09%$0 MNov 2, 2026
66Canada Pension Plan Investment Board160,9000 (0.00%)0.09%$0 MNov 16, 2026
67Rhumbline Advisers157,501-943 (-0.60%)0.09%$0 MNov 10, 2026
68Virtus Investment Advisers, LLC156,322-4,859 (-3.01%)0.09%$0 MNov 12, 2026
69HSBC Holdings PLC142,964New0.08%$0 MNov 16, 2026
70Alliancebernstein L.P.129,310-32,570 (-20.12%)0.07%$0 MNov 16, 2026
71Caitong International Asset Management Co., Ltd123,621+104,320 (+540.49%)0.07%$0 MOct 29, 2026
72ADAR1 Capital Management, LLC119,500-2,632 (-2.16%)0.07%$0 MNov 16, 2026
73Deutsche Bank AG\114,236-20,114 (-14.97%)0.06%$0 MNov 6, 2026
74Ameriprise Financial Inc107,820New0.06%$0 MNov 16, 2026
75Ieq Capital, LLC107,474-15,474 (-12.59%)0.06%$0 MNov 10, 2026
76Group One Trading LLC107,068+25,511 (+31.28%)0.06%$0 MNov 10, 2026
77Price T Rowe Associates Inc /MD/104,2510 (0.00%)0.06%$0 MNov 16, 2026
78State of Alaska, Department of Revenue100,000New0.06%$0 MOct 15, 2026
79Russell Investments Group, Ltd.95,084+44,579 (+88.27%)0.05%$0 MNov 6, 2026
80Aigen Investment Management, LP79,568New0.04%$0 MNov 16, 2026
81MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.78,736-3,723 (-4.51%)0.04%$0 MNov 16, 2026
82Brevan Howard Capital Management LP77,876+67,674 (+663.34%)0.04%$0 MNov 16, 2026
83Mariner, LLC77,260-95,561 (-55.29%)0.04%$0 MNov 12, 2026
84BNP Paribas Financial Markets76,128+40,497 (+113.66%)0.04%$0 MNov 12, 2026
85Profund Advisors LLC73,294-21,915 (-23.02%)0.04%$0 MOct 29, 2026
86Orion Porfolio Solutions, LLC73,263-140,600 (-65.74%)0.04%$0 MNov 12, 2026
87IMC-Chicago, LLC69,791New0.04%$0 MNov 5, 2026
88Invesco Ltd.64,043-5,775 (-8.27%)0.04%$0 MNov 12, 2026
89Vanguard Global Advisers, LLC61,845+687 (+1.12%)0.03%$0 MNov 13, 2026
90Los Angeles Capital Management LLC60,805-44,308 (-42.15%)0.03%$0 MNov 12, 2026
91Barclays PLC53,983+3,586 (+7.12%)0.03%$0 MNov 6, 2026
92MetLife Investment Management, LLC53,434-17,987 (-25.18%)0.03%$0 MNov 16, 2026
93WINTON GROUP Ltd52,400+27,500 (+110.44%)0.03%$0 MNov 12, 2026
94Spark Investment Management LLC44,000New0.02%$0 MNov 13, 2026
95Graham Capital Management, L.P.43,878+21,021 (+91.97%)0.02%$0 MNov 16, 2026
96Mercer Global Advisors Inc /adv43,745-62,825 (-58.95%)0.02%$0 MNov 16, 2026
97Pale Fire Capital SE42,543New0.02%$0 MNov 13, 2026
98LPL Financial LLC39,681+8,211 (+26.09%)0.02%$0 MNov 6, 2026
99Manufacturers Life Insurance Company, The38,926-29,291 (-42.94%)0.02%$0 MNov 13, 2026
100Tower Research Capital LLC (TRC)37,252+29,778 (+398.42%)0.02%$0 MNov 16, 2026

All 172 institutional investors, with who bought and sold →

Mutual funds holding Compass Therapeutics, Inc.#

125 funds in 2 countries hold shares worth $75 M (about 19.1% of the company). Since their previous reports 67 added shares and 42 sold, buying $12 M net. By country: USA 123 ($73 M), Sweden 2 ($2 M).
Mutual funds holding Compass Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.6.84 M$15 M3.8%0.14%+86%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.4.19 M$9 M2.3%<0.01%−0.0%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors3.46 M$8 M1.9%<0.01%+9.4%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.79 M$4 M1.00%<0.01%+4.9%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.43 M$3 M0.79%<0.01%+12%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors1.21 M$3 M0.67%0.02%+132%Jun 30, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC1.12 M$2 M0.62%0.04%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC798,947$2 M0.44%<0.01%−0.8%May 31, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.962,801$2 M0.53%<0.01%newJul 31, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.775,001$2 M0.43%0.10%newJun 30, 2026
🇸🇪 HealthInvest Sustainable HealthcareAtle Fund Management AB741,730$2 M0.41%0.43%+88%Jun 30, 2026
🇺🇸 Royce Micro-Cap Trust, Inc.Royce & Associates, LP731,677$2 M0.41%0.18%+119%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.664,018$2 M0.37%<0.01%+2.4%May 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC719,590$2 M0.40%<0.01%newJun 30, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.589,517$1 M0.33%0.08%+120%May 31, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.495,884$1 M0.28%0.03%newJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors440,826$1 M0.24%0.06%+36%Jun 30, 2026
🇺🇸 Vanguard Market Neutral FundThe Vanguard Group, Inc.400,227$1 M0.22%0.15%newJun 30, 2026
🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P.416,737$1 M0.23%0.06%newJul 31, 2026
🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc.325,460$1 M0.18%0.05%−5.7%Jun 30, 2026
🇺🇸 Royce Micro-Cap FundRoyce & Associates, LP323,411$1 M0.18%0.17%+108%Jun 30, 2026
🇸🇪 HealthInvest Small & Mid Cap HealthcareAtle Fund Management AB306,863$1 M0.17%0.53%+69%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC278,340$1 M0.15%<0.01%no changeMay 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.322,390$1 M0.18%<0.01%+14%Jul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC235,188$1 M0.13%<0.01%+5.8%May 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors243,131$1 M0.14%<0.01%+2.4%Jun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC221,492$0 M0.12%<0.01%no changeJun 30, 2026
🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC211,802$0 M0.12%0.17%no changeJun 30, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC232,413$0 M0.13%0.09%+10%Jul 31, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.185,633$0 M0.10%0.27%+17%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC183,040$0 M0.10%0.02%+144%Jun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP166,283$0 M0.09%<0.01%+2041%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC143,605$0 M0.08%<0.01%+2.1%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC158,719$0 M0.09%<0.01%no changeJul 31, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.143,997$0 M0.08%0.03%newJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC109,310$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Royce Capital Fund - Micro-Cap PortfolioRoyce & Associates, LP106,692$0 M0.06%0.17%—Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC121,096$0 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.108,322$0 M0.06%<0.01%+24%Jul 31, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC37,706$0 M0.02%0.12%—Mar 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP101,119$0 M0.06%<0.01%+254%Jul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation85,940$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Optimize Strategy Index ETFSound Capital Solutions, LLC80,160$0 M0.04%0.06%−0.3%Jun 30, 2026
🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC80,059$0 M0.04%0.05%−14%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC79,750$0 M0.04%<0.01%+96%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC73,690$0 M0.04%<0.01%+112%Jun 30, 2026
🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc.73,074$0 M0.04%0.01%−6.7%Jun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC72,192$0 M0.04%0.02%no changeJun 30, 2026
🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company66,295$0 M0.04%0.06%−11%May 31, 2026
🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc.70,331$0 M0.04%0.03%newJun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.64,680$0 M0.04%<0.01%+1.3%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC64,580$0 M0.04%<0.01%−1.2%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.69,505$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC78,857$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.67,910$0 M0.04%<0.01%+15%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.64,864$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company51,859$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC62,629$0 M0.03%<0.01%+12%Jul 31, 2026
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC65,246$0 M0.04%0.06%—Apr 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.46,665$0 M0.03%<0.01%+4.7%May 31, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.46,574$0 M0.03%0.01%newMay 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC57,805$0 M0.03%<0.01%+7.5%Jul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.43,100$0 M0.02%<0.01%−6.1%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC42,214$0 M0.02%<0.01%+21%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC36,349$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC33,831$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors33,428$0 M0.02%<0.01%−0.8%Jun 30, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.32,837$0 M0.02%0.03%newJun 30, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC37,125$0 M0.02%<0.01%−27%Jul 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP36,781$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC27,658$0 M0.02%0.02%+58%May 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC29,258$0 M0.02%0.03%+26%Jun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP33,008$0 M0.02%<0.01%−50%Jul 31, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC28,641$0 M0.02%<0.01%+22%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC27,304$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS25,867$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION23,500$0 M0.01%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC24,537$0 M0.01%0.01%+6.5%Jul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.20,577$0 M0.01%<0.01%+14%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC20,280$0 M0.01%<0.01%+128%Jun 30, 2026
🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS20,090$0 M0.01%0.02%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.19,996$0 M0.01%<0.01%+31%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC20,730$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC17,850$0 M<0.01%<0.01%+27%Jun 30, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP19,635$0 M0.01%<0.01%+706%Jul 31, 2026
🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation16,306$0 M<0.01%0.01%−5.4%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC16,228$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.13,853$0 M<0.01%<0.01%+1.5%Jun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC13,678$0 M<0.01%<0.01%+29%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC13,219$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.14,806$0 M<0.01%<0.01%+7.8%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC14,593$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.11,073$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP13,305$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 State Street SPDR Portfolio MSCI Global Stock Market ETFSSGA Funds Management, Inc.11,048$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC10,733$0 M<0.01%<0.01%−5.0%Jun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management10,621$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS11,915$0 M<0.01%<0.01%+162%Jul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC9,700$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC9,219$0 M<0.01%<0.01%+14%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Compass Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$27 K
3 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$27 K
open market only
Insiders on file
13
since
$59 K-$5.7 M$0Apr 2025: bought $59 K (2 trades), sold $5.7 M (2 trades)Apr 25May 2025: bought $21 K (1 trades), sold $0 (0 trades)MaySep 2026: bought $3 K (1 trades), sold $0 (0 trades)SepOct 2026: bought $18 K (1 trades), sold $0 (0 trades)OctNov 2026: bought $6 K (1 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Compass Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Neil LernerChief Accounting OfficerBuy+10,000$0.590$6 K430,000Form 4
filed Neil LernerChief Accounting OfficerBuy+20,000$0.920$18 K420,000Form 4
filed Neil LernerChief Accounting OfficerBuy+2,500$1.140$3 K400,000Form 4
filed Neil LernerChief Accounting OfficerBuyamended+15,000$1.890$28 K397,500Form 4/A
filed Jonathan AndermanGeneral CounselBuyamended+25,000$1.890$47 K196,000Form 4/A
filed Jonathan AndermanGeneral CounselGrant or award+25,000$1.890$47 K196,000Form 4
filed Neil LernerChief Accounting OfficerGrant or award+15,000$1.890$28 K397,500Form 4
filed Thomas J. SchuetzCHIEF EXECUTIVE OFFICER, DirectorShares withheld for tax-36,687$6.520$239 K6.60 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Compass Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
40.8 M
22.9% of shares · 18.93 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-04-27 11:25 UTC, code T3, resumed 12:00 UTC

Fails to deliver

  • : 31,258 shares at $0.76
  • : 716 shares at $0.80
  • : 165,625 shares at $0.84
  • : 106,430 shares at $0.90
  • : 11,592 shares at $0.86

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Compass Therapeutics, Inc. scorecard#

Passes 2 of the 10 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-35.9%Free cash flow is -35.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$66 M-$66 M in fiscal 2025 against -$30 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$66 MNet income -$66 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-41.3%-41.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities15.0×Current ratio 15.02 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Compass Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Compass Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue00.90————
Research and development56423830201522
General and administrative17151212111312
Operating expenses73575042822834
Operating income−73−57−50−42−82−28−34
Interest and finance income6.47.37.9r2.40.00.10.7
Interest expense and finance costs———00.40.91.2
Other non-operating income (expense)6.47.37.92.4−0.3−1.7−0.6
Income before tax——−42−39−82−29−35
Income tax000000.00.1
Net income including minority interests————−82−30−35
Net income attributable to shareholders−66−49−42−39−82−30−35
Earnings per share, basic-0.42-0.36-0.33-0.37-1.31-0.96-5.19
Earnings per share, diluted————-1.31-0.96-5.19
Shares, weighted average (basic)15813712710563——
Shares, weighted average (diluted)—137——63316.7
Balance sheet
Cash and cash equivalents314324351454725r
Short-term investments178831281520——
Other current assets0.96.01.48.22.63.10.9
Current assets2101331541951475026r
Property, plant and equipment0.10.40.91.62.21.13.8
Right-of-use (leased) assets9.16.71.83.04.10—
Total assets2201401572001545230r
Accounts payable1.62.24.13.40.91.10.6r
Debt due within a year————07.55.6
Current liabilities148.97.81611109.8r
Long-term debt————01.99.3
Lease liabilities (non-current)8.86.30.51.83.00—
Total liabilities23158.318141219r
Retained earnings−431−365−315−273−234−151−122r
Shareholders' equity1971251491821404011r
Total liabilities and equity2201401572001545230r
Shares outstanding178138128126101517.0r
Cash-flow statement
Depreciation and amortization0.30.60.70.80.62.42.1
Share-based compensation8.48.66.15.34.04.00.9
Cash from operating activities−49−45−41−34−20−27−32
Capital expenditure−0.0−0.0−0.0−0.2−1.6−0.1−0.5
Acquisitions, net of cash acquired———0−0.3——
Cash from investing activities−934727−151−1.80.0−0.5
Debt repaid———0−9.4−5.6—
Shares issued138183.17612860—
Cash from financing activities130172.97611949—
Change in cash−1319−11−1109722−32
Report10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Compass Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$5.1 M
Thomas Schuetz
Other top executives, average
$1.4 M
the CEO earned 3.6× this
$100 invested is now
$344
Compass Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Thomas Schuetz$5.1 M$11.4 M$1.4 M$344
2024Thomas J. Schuetz$6.4 M$6.8 M$1.1 M$93

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Compass Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 13

Compass Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Compass Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2020$60 MNo. 1$50 to $250 million110equitySEC
Jun 2020$195 MIssued in a merger or acquisition$50 to $250 million114equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Compass Therapeutics, Inc.#

$80 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.

Lobbying, 2025
$80 K
#1,289 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
—
  • Health Issues1 report

Lobbying firms hired in 2025

Todd Strategy Group $80 K

Compass Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2025$80 K—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Compass Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Compass Therapeutics, Inc. compares in Biotechnology

  • Market cap$137 M · higher than 40% of 726
  • Revenue$0 M · higher than 0% of 647
  • Price / book0.7× · lower than 85% of 534
  • FCF yield-35.9% · higher than 31% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Compass Therapeutics, Inc.🇺🇸$137 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, value.today research, SEC filing, SEC annual report.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Compass Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Compass Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Compass Therapeutics, Inc.? Suggest a correction